Every winter and monsoon season, paediatric wards fill with babies who struggle to breathe. Many of those admissions are driven by respiratory syncytial virus (RSV)—a common virus that is usually mild in older children, but can cause severe bronchiolitis and pneumonia in newborns and young infants.
On 9 September 2026, the World Health Organization took an important practical step: it prequalified the multi-dose vial of the maternal RSV vaccine RSVpreF (ABRYSVO®). This is not just a regulatory headline. Multi-dose vials matter because they can make large-scale vaccination more affordable and logistically easier—especially for programmes that need to reach many pregnant women efficiently.
Why RSV matters so much for babies
According to WHO, RSV is estimated to cause more than 3.6 million hospitalizations and about 100,000 deaths each year in children under five. Almost half of those deaths occur in infants younger than six months—the exact window maternal immunization is designed to protect. Roughly 97% of RSV deaths occur in low- and middle-income countries, and many babies die at home before they ever reach a hospital.
For families in Hyderabad—and for clinicians counselling antenatally—this is why prevention in early infancy is so important. Newborns cannot simply “wait” until they are older; the highest-risk months come first.
How a maternal RSV vaccine protects the baby
RSVpreF is given to the pregnant mother. Protective antibodies transfer across the placenta to the baby before birth, helping shield the infant through roughly the first six months of life—when RSV is most dangerous.
WHO recommends that countries introduce either maternal RSVpreF or the long-acting monoclonal antibody nirsevimab into national programmes. When the maternal vaccine is used, WHO advises giving it in the third trimester from week 28 onwards, to optimize antibody transfer to the baby.
What “multi-dose prequalification” actually changes
WHO had already prequalified the single-dose ABRYSVO presentation in March 2025, and Gavi later moved to establish a maternal RSV vaccine programme. The September 2026 multi-dose prequalification is the logistics and cost milestone: it improves the feasibility of planning large-scale introductions.
Gavi has welcomed the multi-dose prequalification as a step that helps Gavi-eligible countries move toward programme introduction. That global financing pathway is important for equity—even though India’s own national introduction will follow Indian regulatory and policy decisions.
What this means in India right now
WHO prequalification is not the same as automatic availability in Indian clinics. For parents in Hyderabad, the honest message today is:
- This is a major global advance toward preventing severe RSV disease in early infancy.
- India still needs its own pathway: regulatory clearance, national policy decisions, supply, pricing, and programme design.
- Until local guidance is clear, continue the basics we already know save babies: early recognition of breathing difficulty, timely care-seeking, exclusive breastfeeding support, avoiding smoke exposure, and good hand hygiene around newborns.
When India chooses a product strategy, it may favour maternal vaccination, infant monoclonal antibody, or sequenced approaches based on feasibility and coverage—not every country will use the same tool the same way.
Practical counselling points for parents
- Ask during antenatal visits whether RSV prevention options (maternal vaccine or infant antibody) are locally available and recommended for your pregnancy.
- Do not wait for a vaccine to take breathing symptoms seriously in a young infant: fast breathing, chest indrawing, poor feeding, bluish colour, or unusual sleepiness need urgent medical care.
- Multi-dose vaccines require careful cold-chain and open-vial handling in clinics—quality systems matter as much as the product itself.
Bottom line
WHO’s multi-dose prequalification of maternal RSVpreF is genuinely good news for infant health worldwide. It brings us closer to protecting the youngest babies—those who cannot yet advocate for themselves—from one of the leading causes of severe respiratory illness. For Hyderabad families, we will translate this global milestone into local advice as Indian recommendations and availability become clearer.
This article is for general information and education. It is not a substitute for personal medical advice, diagnosis, or treatment. Please consult your obstetrician or paediatrician for decisions about pregnancy immunization and your baby’s care.
Sources
- WHO (9 Sep 2026): WHO prequalifies multi-dose RSV vaccine vial
- Gavi (9 Sep 2026): Gavi welcomes multi-dose RSV maternal vaccine prequalification
- WHO (19 Mar 2025): First maternal RSV vaccine prequalification
- WHO (30 May 2025): WHO recommendations to protect infants against RSV
Leave a Reply